Abstracts tagged "rituximab and clinical trials"

Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Mark Nicolls¹, David Badesch ², Lorinda Chung ³, Robyn Domsic ⁴, Thomas Medsger ⁵, Ashley Pinckney ⁶, Lynette Keyes-Elstein ⁶, Carla D'Aveta ⁶, Meagan Spychala ⁶, R James White ⁷, Paul Hassoun ⁸, Fernando Torres ⁹, Jerry Molitor ¹⁰, Dinesh Khanna ¹¹, Holden Maeker ¹², Beverly Welch ¹³, Ellen Goldmuntz ¹⁴, Roham Zamanian ¹ and -- On Behalf of ASC01 Investigators ¹⁵, ¹Stanford University, Stanford, ²University of Colorado, Denver, ³Stanford University, Palo Alto, CA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, ⁶Rho Federal Systems, Durham, ⁷University of Rochester, Rochester, NY, ⁸Johns Hopkins School of Medicine, Baltimore, ⁹UT Southwestern, Dallas, ¹⁰University of Minnesota, University of Minnesota, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²Stanford, Stanford, ¹³National Institute of Allergy and Infectious Diseases, NIH, Bethesda, ¹⁴NIAID, Washingto, DC, ¹⁵---, USA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…